The International Consortium on Advanced HIV Disease

Advanced HIV Disease

The International Consortium on Advanced HIV Disease (ICAHD)  was formed in December 2017 to addresses current deficiencies in care for those with advanced HIV disease and AIDS, with the primary objective of reducing deaths from AIDS. These patients are complex, suffer from many different infections, and sometimes cancers, and have usually not been in care previously.

The common most serious problems these patients develop include:

  1. Unusual forms and disseminated tuberculosis
  2. Pneumocystis pneumonia
  3. Cryptococcal meningitis
  4. Severe bacterial infections, typically pneumonia
  5. Disseminated histoplasmosis
  6. Toxoplasma encephalitis and brain abscess
  7. Cytomegalovirus retinitis and sometimes colitis
  8. Lymphoma, often in the brain
  9. Cervical or anal squamous cell carcinomas
  10. And other infections, some dependent on the local geography.

Improving the outcome requires access to rapid diagnostics, the key treatments and committed knowledgeable clinicians to treat the patients. Multiple other facets of supportive care improve outcome.

Global Action Fund for Fungal Infections (GAFFI) is one of the organisations supportive of this initiative.

Fungal diseases are neglected worldwide by public health authorities.

GAFFI efforts are directed at:

  • Identifying and publicising gaps in diagnostics and treatments for fungal diseases.
  • Consulting on how services could be improved through facilitating training, encouraging companies to expand their markets and recommending improvements in infrastructure.
  • Estimating the burden of serious fungal diseases, country by country. Over 65 countries with a population >1 million have been addressed, and many are published.
  • Develop, implement and evaluate country-wide diagnostic programs. Guatemala (fungal infections in AIDS) is the first (view).
  • Influence national and international agencies to ‘adopt’ fungal diseases alongside existing programs including TB, microbiology, AMR, NTDs and incorporation of key generic antifungals onto the WHO Essential Medicines List.
  • Focussed diagnostic improvements for GAFFI’s priority diseases.